New drug enatumab tested for tough blood disorder
NCT ID NCT07190261
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a drug called enatumab in 3 adults with relapsed or refractory warm antibody autoimmune hemolytic anemia (wAIHA), a condition where the immune system destroys red blood cells. Current treatments often stop working or cause relapses. Enatumab is given as injections over several weeks to see if it can control the disease. The main goal is to measure how many patients respond to treatment at 3 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- enatumab
- What this could lead to
- If successful, enatumab could offer a new treatment option for people with relapsed or refractory warm antibody autoimmune hemolytic anemia, potentially reducing relapses and improving quality of life.
- What could go wrong
- This is a very small early-phase trial with only 3 participants, so results may not apply broadly. The drug may not work or could cause side effects, and larger studies are needed to confirm any benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking union medical college hospital
Beijing, Shuangfuyuan, NO I., 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test predict clot risk in antiphospholipid syndrome?
- Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
- Engineered immune cells take on rare blood disorders
- Brain scans reveal hidden thinking problems in anemia patients
- Experimental immune therapy for stubborn anemia shows early promise but trial stalls
- Experimental CAR-T therapy takes on stubborn blood disorder